Поиск по акциям

Показать:
Сортировать
Страна
Отрасль
Риск-рейтинг
1
2
3
4
5
6
7
Факторы риска

    Риск дефолта

    1
    2
    3
    4
    5
    6
    7

    Волатильность

    1
    2
    3
    4
    5
    6
    7

    Стресс-тест

    1
    2
    3
    4
    5
    6
    7

    Сложность продажи

    1
    2
    3
    4
    5
    6
    7

    Страновые риски

    1
    2
    3
    4
    5
    6
    7

    Другие риски

    1
    2
    3
    4
    5
    6
    7
Факторы доходности

    Оценка

    1
    2
    3
    4
    5
    6
    7

    Прогноз аналитиков

    1
    2
    3
    4
    5
    6
    7

    Динамика

    1
    2
    3
    4
    5
    6
    7

    Прибыльность

    1
    2
    3
    4
    5
    6
    7

    Рост

    1
    2
    3
    4
    5
    6
    7

    Дивиденды

    1
    2
    3
    4
    5
    6
    7
Найдено: 69

Sino Biopharmaceutical Limited

1177.HK
6

Alibaba Health Information Technology Limited

0241.HK
4

Genscript Biotech Corporation

1548.HK
3

HUTCHMED

0013.HK
4

Regencell Bioscience Holdings Limited

RGC
1

The United Laboratories International Holdings Limited

3933.HK
6

China Medical System Holdings Limited

0867.HK
4

China Resources Pharmaceutical Group Limited

3320.HK
6

Grand Pharmaceutical Group Limited

0512.HK
5

Ascletis Pharma Inc.

1672.HK
2

Sihuan Pharmaceutical Holdings Group Ltd.

0460.HK
4

China Traditional Chinese Medicine Holdings Co. Limited

0570.HK
4

SSY Group Limited

2005.HK
5

SinoMab BioScience Limited

3681.HK
1

Beijing Tong Ren Tang Chinese Medicine Company Limited

3613.HK
6

Modern Dental Group Limited

3600.HK
5

CK Life Sciences Int'l.,

0775.HK
2

Kaisa Health Group Holdings Limited

0876.HK
3

Lee's Pharmaceutical Holdings Limited

0950.HK
5

JBM

2161.HK
5

CPBIO Holding Company Limited

3839.HK
3

Vincent Medical Holdings Limited

1612.HK
4

Jacobson Pharma Corporation Limited

2633.HK
4

Perfect Medical Health Management Limited

1830.HK
4

C-MER Medical Holdings Limited

3309.HK
4

Uni-Bio Science Group Limited

0690.HK
4

China Biotech Services Holdings Limited

8037.HK
2

Tycoon Group Holdings Limited

3390.HK
3

King International Investment Limited

0928.HK
2

Town Health International Medical Group Limited

3886.HK
4

OrbusNeich Medical Group Holdings Limited

6929.HK
5

China Health Group Limited

0673.HK
2

Cellyan Biotechnology Co., Ltd

HKPD
3

Extrawell Pharmaceutical Holdings Limited

0858.HK
2

China NT Pharma Group Company Limited

1011.HK
2

EC Healthcare

2138.HK
3

Hony Media Group

0419.HK
1

Dawnrays Pharmaceutical

2348.HK
5

Good Fellow Healthcare Holdings Limited

8143.HK
3

Joyzyme Group Limited

8622.HK
2

Kato

2189.HK
5

Human Health Holdings Limited

1419.HK
4

Beijing Health

2389.HK
3

Pak Fah Yeow International Limited

0239.HK
4

Pa Shun International Holdings Limited

0574.HK
2

Wai Yuen Tong Medicine Holdings Limited

0897.HK
3

Shenzhen Neptunus Interlong Bio-technique Company Limited

8329.HK
3

PuraPharm Corporation Limited

1498.HK
3

Wanjia Group Holdings Limited

0401.HK
2

Regent Pacific Group Limited

0575.HK
2

UMP Healthcare Holdings Limited

0722.HK
4

AMCO United Holding Limited

0630.HK
3

Kontafarma China Holdings Limited

1312.HK
3

Kelfred Holdings Limited

1134.HK
3

China Regenerative Medicine International Limited

8158.HK
3

Green International Holdings Limited

2700.HK
1

Qianhai Health Holdings Limited

0911.HK
3

Arts Optical International Holdings Limited

1120.HK
3

Grand Brilliance Group Holdings Limited

8372.HK
3

Tian An Medicare Limited

0383.HK
3

Tianda Pharmaceuticals Limited

0455.HK
3

Miricor Enterprises Holdings Limited

1827.HK
3

Medicskin Holdings Limited

8307.HK
3

MediNet Group Limited

8161.HK
3

Zhong Yuan Bio-Technology Holdings Limited

ZHYBF
1

Global Pharmatech, Inc.

GBLP
2

Medical Supply International USA, Inc.

MSIU

DH Enchantment, Inc.

ENMI
2

Global Cord Blood Corporation

CO
3
Портфели гуру

Куда инвестируют крупнейшие фонды и легенды рынка

Ли Лу

Ли Лу

Himalaya Capital Management

Доходность за Q2 2026:10.41%

Состав портфеля:

+6 активов
Натаниэль «Нэт» Саймонс

Натаниэль «Нэт» Саймонс

Meritage Group

Доходность за Q2 2026:1.02%

Состав портфеля:

+10 активов
Перейти в раздел